Wu Weizhong, the Director of the Institute of Liver Cancer and Deputy Director of Cell Therapy Research Center of Zhongshan Hospital affiliated to Fudan University
Dr Zhu Li, the Chief Strategy Officer of Nanjing Legend Biotechnology Co., visited Converd and had in-depth communication with Dr. Hu Fang, Chairman of Converd,
Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.
On January 13, 2018, Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to our company for academic exchanges.
Converd has completed and moved to its new R & D center in Hangzhou. The Center holds 1,000 m2 area of laboratory space for Molecular and Cellular biology
Converd has received investment in shares from CR Pharmaceutical(华润生命科学). This is a part of Converd’s B series financing, which also includes investments from Nanjing Jingyong Healthcare Capitals.